A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer - Trial NCT06246110

Name: Clinical Trial NCT06246110
Creator: Eikon Therapeutics
Keywords: NSCLC, EIK1001, Phase 2, drug, clinical trial, United States of America

Access comprehensive clinical trial information for NCT06246110 through Pure Global AI's free database. This Phase 2 trial is sponsored by Eikon Therapeutics and is currently Recruiting. The study focuses on NSCLC. Target enrollment is 70 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database

840K+ Trials

NCT06246110

Phase 2

Recruiting

drug

Trial Details

ClinicalTrials.gov • NCT06246110

View on ClinicalTrials.gov

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer

Study Focus

Disease/Condition

NSCLC

Drug/Device/Intervention

EIK1001

Study Type

Interventional

Intervention Type

drug

Sponsor & Location

Primary Sponsor

Eikon Therapeutics

Location

Baltimore,White Plains, United States of America

Timeline & Enrollment

Phase

Phase 2

Start Date

Feb 06, 2024

End Date

Dec 01, 2027

Enrollment

70 participants

Primary Outcome

Percentage of participants with safety event during treatment

Summary

This study is for patients with advanced/metastatic non-small cells lung cancer (NSCLC) who have not received any treatment through the vein for the advanced disease.

Data Source

Registry

ClinicalTrials.gov

Trial ID

NCT06246110

Type

Non-Device Trial